Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme (2021)

First Author: Langley Ruth E.

Attributed to: Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care funded by MRC

No abstract provided

Type: Journal Article/Review

Volume: 397

Parent Publication: LANCET

Issue: 10274

ISSN: 0140-6736